Kerendia Tablet, Film Coated
Product Images NDC 50419-540

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Kerendia (NDC 50419-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Kerendia 20 mg Label (Image 01)

Kerendia (finerenone) 20 mg film-coated tablets packaging label. The label displays the product name and strength, dosage form as tablets, quantity of 30 tablets, and manufacturer Bayer HealthCare Pharmaceuticals Inc. It includes dosage instruction notes and storage conditions with temperature parameters, with barcode and lot information visible.*

FDA Label Image

Kerendia 10 mg Label (Image 02)

Kerendia (finerenone) tablets 10 mg film-coated tablets packaging label. The carton contains 30 tablets and is labeled as Rx only. Manufactured by Bayer HealthCare Pharmaceuticals Inc. The label includes storage instructions and warnings to keep out of reach of children.*

FDA Label Image

Kerendia Chemical Structure (Image 03)

Chemical structure diagram of Finerenone, illustrating its molecular framework including rings and functional groups such as a nitrile group (–CN), amine group (–NH2), and methoxy group (–OCH3).*

FDA Label Image

Figure 1 Time To Occurence Of Kidney Failure (Image 04)

A line graph depicting the cumulative incidence probability of a first event over a 42-month period for two treatment groups: Kerendia and Placebo. The X-axis represents time in months and the Y-axis represents cumulative incidence probability from 0 to 0.5. The graph includes patient counts at risk for each time interval below the X-axis.*

FDA Label Image

Time To Occurrence Of Cv Death (Image 05)

A cumulative incidence probability graph comparing the planned treatment outcomes of Finerenone (Kerendia) versus placebo over 42 months. The x-axis represents time to first event in months, and the y-axis shows cumulative incidence probability. The graph includes patient numbers at risk for each group at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.